Published: November 15, 2020
SPR has officially replaced anti-malaria drug HCQ with anti-parasite drug ivermectin in its covid-19 prophylaxis and early treatment protocol recommended to doctors and authorities.
Ivermectin was already listed as an ‘additional component’ of the SPR protocol, but recent controlled randomized trials and large observational studies have confirmed a superior performance, showing covid mortality reductions of up to 90% even in severe cases.
For more in-depth data on ivermectin, doctors and health authorities are asked to study the comprehensive information provided by the US Front-Line Covid-19 Critical Care Alliance (FLCCC), who consider ivermectin “a potential global solution to the covid-19 pandemic”.
In stark contrast to the success of ivermectin, the President of the European Society of Intensive Care Medicine (ESICM) recently officially advised against the use of the very expensive “anti-viral” drug remdesivir (due to its inefficacy and liver toxicity). Remdesivir is the first and only “covid drug” approved by the US FDA and European health authorities.